HLB SCIENCE Inc. Logo

HLB SCIENCE Inc.

Develops drugs and diagnostics for infectious, immune, and Alzheimer's diseases.

343090 | KO

Overview

Corporate Details

ISIN(s):
KR7343090007
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로 128씨동 1314호, 서울특별시

Description

HLB SCIENCE Inc. is a biopharmaceutical company specializing in the development of innovative drugs and diagnostics for infectious and immune-related diseases. The company's primary research focuses on creating therapeutics for sepsis, superbacteria infections, and Alzheimer's disease. Its key pipeline candidate for sepsis, DD-S052P, is a novel antibiotic designed to eliminate both bacteria and their associated endotoxins to mitigate cytokine storms. For Alzheimer's disease, HLB SCIENCE is advancing DD-A279, a treatment that modulates lipopolysaccharides (LPS) and gram-negative bacteria in the central nervous system. This therapeutic effort is complemented by the development of DD-A514, a diagnostic kit for the early detection of Alzheimer's.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2026-01-08 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 90.7 KB
2026-01-06 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.8 KB
2025-12-23 00:00
주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)
Korean HTML 4.7 KB
2025-09-17 00:00
주주총회소집결의
Korean HTML 7.2 KB
2025-09-17 00:00
주주명부폐쇄기간또는기준일설정
Korean HTML 4.1 KB
2025-09-17 00:00
[첨부추가]주요사항보고서(회사합병결정)
Korean HTML 52.4 KB
2025-06-19 00:00
기업설명회(IR)개최결과
Korean HTML 6.7 KB
2025-05-12 00:00
주식등의대량보유상황보고서(약식)
Korean HTML 65.1 KB
2025-05-12 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.2 KB
2025-05-09 00:00
전환가액의조정 (제4회차)
Korean HTML 10.1 KB
2025-04-23 00:00
본점소재지변경
Korean HTML 5.0 KB
2025-03-25 00:00
정기주주총회결과
Korean HTML 20.0 KB
2025-03-25 00:00
주식매수선택권부여에관한신고
Korean HTML 16.6 KB
2025-03-17 00:00
감사보고서제출
Korean HTML 9.7 KB
2025-03-17 00:00
사업보고서 (2024.12)
Korean HTML 1022.1 KB

Automate Your Workflow. Get a real-time feed of all HLB SCIENCE Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB SCIENCE Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB SCIENCE Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Keros Therapeutics, Inc. Logo
Develops protein therapeutics for disorders linked to TGF-β signaling.
United States of America
KROS
Kura Oncology, Inc. Logo
Clinical-stage biopharma company developing precision medicines for cancer treatment.
United States of America
KURA
Larimar Therapeutics, Inc. Logo
A clinical-stage biotech developing treatments for complex rare diseases.
United States of America
LRMR
Lexaria Bioscience Corp. Logo
A biotech company with a patented platform to improve oral drug delivery and absorption.
United States of America
LEXX
LigaChem Biosciences Inc. Logo
Clinical-stage biopharma developing ADCs, immuno-oncology drugs, and small molecules.
South Korea
141080
Linical Co., Ltd. Logo
A global CRO providing a full spectrum of drug development services for biopharma.
Japan
2183
Lipigon Pharmaceuticals AB Logo
A clinical-stage company developing therapeutics for lipid-related disorders.
Sweden
LPGO
Lipum AB Logo
Clinical-stage biopharma developing novel treatments for chronic inflammatory diseases.
Sweden
LIPUM
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Clinical-stage pharma company developing PP2A inhibitors to enhance cancer therapies.
United States of America
LIXT
Pre-clinical biotech company using AI for drug discovery and biodefense.
United States of America
RENB

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.